Dicot Q2 Report Release Date Change

Report this content

Press release: Uppsala, August 12, 2019. Dicot AB (publ), developer of drugs targeting sexual dysfunction, today announced that the company has decide to bring forward the release date of the next quarterly report by one week. It will now be released on 22 August 2019 rather than the original planned release date of 29 August 2019. This is due to satify the need to include Q2 financial data in the previously announced Rights Issue (link) Investment Memorandum.

For more information, please contact:

Julie Silber

CFO/Investor Relations Director, Dicot

Tel.: +46-79-3486277

Email: julie.silber@dicot.se

About Dicot AB (publ)

Dicot's business concept is to develop the product LibiguinTM as a drug for the treatment of sexual dysfunctions. The development takes place in-house up to clinical phases. It is the company's intention to subsequently enter into strategic alliances at appropriate times, or alternatively conduct a trade sale, with established major pharmaceutical companies to be able to introduce LibiguinTM on the world market. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. www.dicot.se

This information is such that Dicot AB is required to make public in accordance with the EU’s Market Abuse Regulation (MAR). The information was made public by the Company’s contact person above on August 12, 2019.


Documents & Links